SCHEMBL20548836

SCHEMBL20548836

C[Si](C)(C)CCOCn1ccc2c(-c3cnn(C(CC(N)=O)C4CCCC4)c3)ncnc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 9/20 0.42
JAK2 O60674 8/20 0.42
JAK3 P52333 6/20 0.42
TYK2 P29597 4/20 0.42
ABL1 P00519 3/20 0.41
DAPK3 O43293 2/20 0.41
PAK4 O96013 2/20 0.41
RET P07949 2/20 0.41
LTK P29376 2/20 0.41
CSNK1A1 P48729 2/20 0.41
CLK2 P49760 2/20 0.41
TNK2 Q07912 2/20 0.41
ROCK1 Q13464 2/20 0.41
DYRK1A Q13627 2/20 0.41
IKBKE Q14164 2/20 0.41
NTRK3 Q16288 2/20 0.41
NTRK2 Q16620 2/20 0.41
LRRK2 Q5S007 2/20 0.41
TAOK1 Q7L7X3 2/20 0.41
CAMK1D Q8IU85 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004359 1.00 JAK1 (0.42) JAK1JAK2JAK3TYK2ABL1
SCHEMBL3006039 0.93 JAK1 (0.41) JAK1JAK2JAK3TYK2ABL1
SCHEMBL3001747 0.93 JAK1 (0.41) JAK1JAK2JAK3TYK2ABL1
SCHEMBL19098147 0.92 JAK1 (0.40) JAK1JAK2JAK3TYK2ABL1
SCHEMBL99643 0.92 JAK1 (0.41) JAK1JAK2JAK3TYK2ABL1
SCHEMBL3014612 0.92 JAK1 (0.41) JAK1JAK2JAK3TYK2ABL1
SCHEMBL13243678 0.92 JAK1 (0.41) JAK1JAK2JAK3TYK2ABL1
SCHEMBL31330281 0.92 JAK1 (0.41) JAK1JAK2JAK3TYK2ABL1
SCHEMBL20670281 0.90 JAK1 (0.41) JAK1JAK2JAK3TYK2ABL1
SCHEMBL100088 0.88 JAK1 (0.41) JAK1JAK2JAK3TYK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3398952-B1 SYNTHESIS PROCESS OF RUXOLITINIB CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2021-07-14 EP disclosed
US-10562904-B2 Synthesis process of ruxolitinib CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-02-18 US disclosed
US-20190023712-A1 SYNTHESIS PROCESS OF RUXOLITINIB CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-01-24 US disclosed
EP-3398952-A1 SYNTHESIS PROCESS OF RUXOLITINIB Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2018-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562904-B2 Synthesis process of ruxolitinib JAK3, JAK1, JAK2 JAK1 2/4885JAK2 3/4885JAK3 1/4885
US-20190023712-A1 SYNTHESIS PROCESS OF RUXOLITINIB JAK3, JAK1, JAK2 JAK1 2/4885JAK2 3/4885JAK3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.